Growth factors used to mean one thing in skincare: proteins harvested from human or animal cells, sold at eye-watering prices, and surrounded by a faint discomfort about where exactly they came from. Biossance's Squalane + Growth Factor Firming Moisturizer, released in 2024, rewrites that premise entirely by growing its growth factor inside a tobacco plant. The active, sh-polypeptide-76, is a recombinant protein produced through bioengineering of Nicotiana benthamiana — a vegan, lab-grown biomimetic stand-in for the mammalian versions, and a tidy illustration of what happens when a biotech company decides to bring its production tricks to your moisturizer. It's a genuinely novel answer to an old ethical and supply problem, and it reframes the whole growth-factor conversation around what's possible rather than what's traditional.
That biotech lineage isn't incidental. Biossance is owned by Amyris, the company that pioneered fermenting squalane from sugarcane rather than extracting it from shark liver or olives, and the brand's whole identity rests on engineering its way around the usual sourcing problems. The squalane sits at position five on the INCI list here, providing substantial skin-identical emollience — a well-established, broadly tolerated lipid that cushions without clogging and plays nicely even with acne-prone skin. Around it, the formula builds out a deliberate sustainable-bioengineering structure. Eleven amino acids — arginine, aspartic acid, glycine, alanine, serine, valine, isoleucine, proline, threonine, histidine, and phenylalanine — form a comprehensive natural moisturizing factor framework, the well-validated stuff your skin uses to hold onto its own water and keep the barrier supple. A cyclic peptide complex of hexapeptide-9 and hexapeptide-40, alongside a vegan recombinant collagen, supplies promising collagen-pathway and surface-plumping support. There's also a saccharomyces ferment filtrate adding further bioactive support and pseudostellaria root for a traditional botanical note. And the headline growth factor sits at the tail of the ingredient list, the typical placement for a sophisticated, low-dose active that's meant to signal rather than bulk-fill. It's worth dwelling for a moment on why that placement isn't a red flag the way it would be for a cheap-active formula: growth factors and signaling peptides work at extremely low concentrations, so their position near the end of the INCI is expected rather than evidence of underdosing, and the supporting cast of squalane, amino acids, and peptides is doing the bulk of the visible work while the growth factor plays its quieter, longer game.
In the hand and on the face, it reads as a lightweight cushion cream that absorbs to a satin finish — substantial enough to feel like a treatment, not so rich it sits on top of the skin or interferes with makeup. It's fragrance-free, which is the quiet hero detail for anyone with reactive skin, and it suits a genuinely broad range of skin types, sensitive included. Skin feels immediately cushioned and looks plumper from the first use; that part is the humectants and emollients doing honest, instant work. The cumulative anti-aging benefits — the firming the name promises — are the slower play, realistically unfolding over eight to twelve weeks of consistent use, which is the right horizon to judge a peptide-and-growth-factor formula against rather than expecting transformation in days.
Honesty requires sitting with the central caveat: the growth factor mechanism is emerging evidence. Recombinant plant-produced growth factors are a real and credible frontier, and the structural biomimicry is sound, but the body of independent topical research is younger and thinner than what backs the squalane, the amino acids, or even the peptides. The medium data-confidence rating reflects that — this is a 2024 product, recent enough that the long-term picture is still filling in, though it has accumulated a healthy review base in the hundreds. There's also a smaller, more philosophical limitation worth naming: the recombinant, bioengineered nature of these ingredients, which is precisely the selling point for some shoppers, will give pause to anyone instinctively skeptical of lab-made actives. The formula can't be both for them and not for them, and it doesn't try to be.
On value, $64 for 50ml lands squarely in mid-tier indie-luxury territory — not cheap, not a value-priority pick, but reasonable given what's inside and where the category prices out. Growth-factor moisturizers routinely command dramatically higher prices, and against that backdrop, Biossance delivering a vegan biomimetic growth factor, a real squalane signature, a full amino-acid framework, and a peptide complex at this price reads as fair rather than inflated. The established brand heritage helps; this is a company with a coherent scientific story and a track record, not a hype balloon, and the cruelty-free, vegan formulation is genuine rather than decorative.
The natural buyer is someone curious about growth factors but unwilling to pay luxury-clinic prices, a committed vegan or cruelty-free shopper, or anyone who finds the sustainable-bioengineering angle as compelling as the skincare itself. Normal, combination, dry, and sensitive skin all sit comfortably in its wheelhouse, and the fragrance-free build makes it an easy recommendation for barrier-conscious routines targeting early aging, dehydration, and a compromised barrier in need of cushioning. Anyone whose top priority is rock-bottom value, or who needs a long, settled evidence base before they'll trust an active, should wait or look elsewhere. For everyone in between, this is one of the more genuinely interesting moisturizer launches of its year — a thoughtful formula that earns its price through innovation rather than packaging, and that happens to feel lovely on the skin while it's at it. If you've been intrigued by growth factors but balked at both the prices and the sourcing, this is the most accessible and ethically tidy way to dip a toe in, and the rest of the formula is good enough that you're not gambling the whole purchase on one emerging active.
